FDANear Approval for Varivax Chicken Pox Vaccine
The FDA is close to final approval of Varivax, a chicken pox vaccine, with about a million U.S. children affected yearly and thousands hospitalized or killed by related infections. Kaiser Permanente found missed work costs and health burdens, noting adults endure more severe illness. The shot targets healthy children, with a two-dose plan for those under 12 and a planned initial plus booster for older recipients. Merck expects market entry within six weeks post approval, and federal programs may offer free vaccines to the poor or uninsured.
MENTIONED IN THIS ARTICLE
California
Kaiser Permanente
Adkins
Merck & Co
Government boosts shots for children
Aiming to raise immunization rates, the Clinton administration pours millions into child vaccines as CDC data show 1993 rates up to 72 percent for the core DTP, polio, and MMR series. Experts urge local action, doctors to vaccinate during visits, and earlier protection before school entry.
Also Mentioned on This Page
CFI
Me Jemae
Gannett News Service
US. Food and Drug Administration
United States
W. Main Mesa
Bree
Federal Office
Ahd Galt Vce
Ee GaGa
Washington
Clinton
Pamela Adkins
Merck and Co
Institute of Medicine
Journal of the Association
VISA
Metropolitan Federal Bank
Scottsdale
East Indian School Road
Mesa
East Main Street
Isb